Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes

Molecular and Cellular Endocrinology

Volumn 367, Issue 1-2, 2013, Pages 116-123

  Pan, Yu ^a   Shu, Jin Lian ^a   Gu, Hui Fang ^b   Zhou, Dong Chi ^b   Liu, Xiao Li ^a   Qiao, Qing Yan ^b   Fu, Shun Kun ^b   Gao, Feng Hou ^a   Jin, Hui Min ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

3T3L1 adipocytes; Erythropoietin receptor (EPOR); Insulin resistance (IR); Recombinant human erythropoietin (rHuEPO); SiRNA

Indexed keywords

ADIPONECTIN; ERYTHROPOIETIN RECEPTOR; GLUCOSE; LEPTIN; MESSENGER RNA; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; SMALL INTERFERING RNA; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN 3T3; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

3T3-L1 CELLS; ADIPOCYTES; ADIPONECTIN; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; ERYTHROPOIETIN; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; INSULIN RESISTANCE; K562 CELLS; LEPTIN; MICE; MODELS, BIOLOGICAL; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAINING AND LABELING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873568635     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.12.027     Document Type: Article

References (38)

1. Aguilera A., Bajo M.A., Díez J.J., Ruiz-Caravaca M.L., Vicenta Cuesta M., Alvarez V., Codoceo R., Selgas R. Effects of human recombinant erythropoietin on inflammatory status in peritoneal dialysis patients. Adv. Perit. Dial. 2002, 18:200-205.
2. Allegra V., Mengozzi G., Martimbianco L., Vasile A. Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients. Am J Nephrol 1996, 16(4):304-308.
3. Anand S., Muthusamy V.S., Sujatha S., Sangeetha K.N., Bharathi Raja R., Sudhagar S., Poornima Devi N., Lakshmi B.S. Aloe emodin glycosides stimulates glucose transport and glycogen storage through PI3K dependent mechanism in L6 myotubes and inhibits adipocyte differentiation in 3T3L1 adipocytes. FEBS Lett. 2010, 584(14):3170-3178.
4. Beleslin-čokić B.B., Cokić V.P., Wang L., Piknova B., Teng R., Schechter A.N., Noguchi C.T. Erythropoietin and hypoxia increase erythropoietin receptor and nitric oxide levels in lung microvascular endothelial cells. Cytokine 2011, 54(2):129-135.
5. Caperuto L.C., Anhê G.F., Amanso A.M., Ribeiro L.M., Medina M.C., Souza L.C., Carvalho O.M., Bordin S., Saad M.J., Carvalho C.R. Distinct regulation of IRS proteins in adipose tissue from obese aged and Dex-treated rat. Endocrine 2006, 29(3):391-398.
6. Ayerden Ebinç F., Ebinç H., Derici U., Aral A., Aybay C., Taçoy G., Koç E., Mutluay R., Altok Reis K., Erten Y., Arinsoy T., Sindel S. The relationship between adiponectin levels and proinflammatory cytokines and left ventricular mass in dialysis patients. Nephrol 2009, 22(2):216-223.
7. Echiqoya M.H., Obikane K., Nakashima T., Sasaki S. Glomerular localization of erythropoietin receptor mRNA and protein in neonatal and mature mouse kidney. Nephron. Exp. Nephrol. 2005, 100(1):e21-e29.
8. Farrell F., Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004, 9(Suppl 5):18-30.
9. Hamed S., Egozi D., Kruchevsky D., Teot L., Gilhar A., Ullmann Y. Erythropoietin improves the survival of fat tissue after its transplantation in nude mice. PLoS One 2010, 5(11):e13986.
10. Katz O., Stuible M., Golishevski N., Lifshitz L., Tremblay M.L., Gassmann M., Mittelman M., Neumann D. Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J. Endocrinol. 2010, 205(1):87-95.
11. Khedr E., El-Sharkawy M., Abdulwahab S., Eldin E.N., Ali M., Youssif A., Ahmed B. Effect of recombinant human erythropoietin on insulin resistance in hemodialysis patients. Hemodial Int. 2009, 13(3):340-346.
12. Kokot F., Wiecek A., Mesjasz J., Adamczak M., Spiechowicz U. Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients. Nephrol. Dial. Transpl. 1998, 13(5):1200-1205.
13. Kubota N., Terauchi Y., Yamauchi T., Kubota T., Moroi M., Matsui J., Eto K., Yamashita T., Kamon J., Satoh H., Yano W., Froguel P., Nagai R., Kimura S., Kadowaki T., Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 2002, 277(29):25863-25866.
14. Li Y., Takemura G., Okada H., Miyata S., Maruyama R., Li L., Higuchi M., Minatoguchi S., Fujiwara T., Fujiwara H. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc. Res. 2006, 71(4):684-694.
15. Lundby C., Hellsten Y., Jensen M.B., Munch A.S., Pilegaard H. Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle. J. Appl. Physiol. 2008, 104(4):1154-1160.
16. Mak R.H. Metabolic effects of erythropoietin in patients on peritoneal dialysis. Pediatr. Nephrol. 1998, 12(8):660-665.
17. Mikolás E., Cseh J., Pap M., Szijárto I.A., Balogh A., Laczy B., Beko V., Fisi V., Molnár G.A., Mérei A., Szeberényi J., Wittmann I. Effects of erythropoietin on glucose metabolism. Horm. Metab. Res. 2012, 44(4):279-285.
18. Mirmohammadsadegh A., Marini A., Gustrau A. Role of erythropoietin receptor expression in malignant melanoma. J. Invest. Dermatol. 2010, 130(1):201-210.
19. Moore E.M., Bellomo R., Nichol A.D. Erythropoietin as a novel brain and kidney protective agent. Anaesth. Intens. Care 2011, 39(3):356-372.
20. Groeneveld M.P., Huang-Doran I., Semple R.K. Adiponectin and leptin in human severe insulin resistance - Diagnostic utility and biological insights. Biochimie 2012, Epub ahead of print.
21. Müller G., Ertl J., Gerl M., Preibisch G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J. Biol. Chem. 1997, 272(16):10585-10593.
22. Ohashi N., Kato A., Misaki T., Sakakima M., Fujigaki Y., Yamamoto T., Hishida A. Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern. Med. 2008, 47(6):485-491.
23. Kes P., Basić-Jukić N., Furić-Cunko V. Pleiotropic effects of erythropoietin. Acta Med Croat 2009, (Suppl. 1):46-53.
24. Papworth K., Bergh A., Grankvist K., Ljungberg B., Rasmuson T. Expression of erythropoietin and its receptor in human renal cell carcinoma. Tumour Biol. 2009, 30(2):86-92.
25. Rasic-Milutinovic Z., Perunicic-Pekovic G., Cavala A., Gluvic Z., Bokan L., Stankovic S. The effect of recombinant human erythropoietin treatment on insulin resistance and inflammatory markers in non-diabetic patients on maintenance hemodialysis. Hippokratia 2008, 12(3):157-161.
26. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37(12):1595-1607.
27. Rundqvist H., Rullman E., Sundberg C.J., Fischer H., Eisleitner K., Ståhlberg M., Sundblad P., Jansson E., Gustafsson T. Activation of the erythropoietin receptor in human skeletal muscle. Eur. J. Endocrinol. 2009, 161(3):427-434.
28. Sakoda H., Ogihara T., Anai M., Funaki M., Inukai K., Katagiri H., Fukushima Y., Onishi Y., Ono H., Fujishiro M., Kikuchi M., Oka Y., Asano T. Dexamethasone-induced insulin resistance in 3T3L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes 2000, 49(10):1700-1708.
29. Scully M.S., Ort T.A., James I.E., Bugelski P.J., Makropoulos D.A., Deutsch H.A., Pieterman E.J., van den Hoek A.M., Havekes L.M., Dubell W.H., Wertheimer J.D., Picha K.M. A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes. Exp. Diabetes Res. 2011, 2011:910159.
30. Shinohara K., Shoji T., Emoto M., Tahara H., Koyama H., Ishimura E., Miki T., Tabata T., Nishizawa Y. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J. Am. Soc. Nephrol. 2002, 13(7):1894-1900.
31. Siew E.D., Ikizler T.A. Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease. Semin. Dial. 2010, 23(4):378-382.
32. Sinclair A.M., Coxon A., McCaffery I., Kaufman S., Paweletz K., Liu L., Busse L., Swift S., Elliott S., Begley C.G. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010, 115(21):4264-4272.
33. Spaia S., Pangalos M., Askepidis N., Pazarloglou M., Mavropoulou E., Theodoridis S., Dimitrakopoulos K., Milionis A., Vayonas G. Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron 2000, 84(4):320-325.
34. Stacker S.A., Runting A.S., Caesar C., Vitali A., Lackmann M., Chang J., Ward L., Wilks A.F. The 3T3-L1 fibroblast to adipocyte conversion is accompanied by increased expression of angiopoietin-1, a ligand for tie2. Growth Factors 2000, 18(3):177-191.
35. Teng R., Gavrilova O., Suzuki N., Chanturiya T., Schimel D., Hugendubler L., Mammen S., Yver D.R., Cushman S.W., Mueller E., Yamamoto M., Hsu L.L., Noguchi C.T. Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. Nat. Commun. 2011, 2:520.
36. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997, 389(6651):610-614.
37. Watowich S.S. The erythropoietin receptor: molecular structure and hematopoietic signaling pathways. J. Invest. Med. 2011, 59(7):1067-1072.
38. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M.L., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 7(8):941-946.